167 related articles for article (PubMed ID: 7570046)
1. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.
Wiseman GA; Kvols LK
Semin Nucl Med; 1995 Jul; 25(3):272-8. PubMed ID: 7570046
[TBL] [Abstract][Full Text] [Related]
2. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
3. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.
Hoefnagel CA
Eur J Nucl Med; 1994 Jun; 21(6):561-81. PubMed ID: 7915987
[TBL] [Abstract][Full Text] [Related]
4. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
5. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
6. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775
[TBL] [Abstract][Full Text] [Related]
7. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
[TBL] [Abstract][Full Text] [Related]
8. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.
McCarthy KE; Woltering EA; Espenan GD; Cronin M; Maloney TJ; Anthony LB
Cancer J Sci Am; 1998; 4(2):94-102. PubMed ID: 9532411
[TBL] [Abstract][Full Text] [Related]
9. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue.
Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B
Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846
[TBL] [Abstract][Full Text] [Related]
10. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours.
Taal BG; Hoefnagel CA; Valdés Olmos RA; Boot H
Eur J Cancer; 1996 Oct; 32A(11):1924-32. PubMed ID: 8943676
[TBL] [Abstract][Full Text] [Related]
11. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Kaltsas GA; Mukherjee JJ; Grossman AB
Ann Oncol; 2001; 12 Suppl 2():S47-50. PubMed ID: 11762352
[TBL] [Abstract][Full Text] [Related]
12. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.
Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):3-8. PubMed ID: 9002740
[TBL] [Abstract][Full Text] [Related]
13. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
14. Indium-111-pentetreotide scintigraphy in children with neuroblast-derived tumors.
Manil L; Edeline V; Lumbroso J; Lequen H; Zucker JM
J Nucl Med; 1996 Jun; 37(6):893-6. PubMed ID: 8683306
[TBL] [Abstract][Full Text] [Related]
15. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
[TBL] [Abstract][Full Text] [Related]
16. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
17. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
18. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
McCarthy KE; Woltering EA; Anthony LB
Q J Nucl Med; 2000 Mar; 44(1):88-95. PubMed ID: 10932605
[TBL] [Abstract][Full Text] [Related]
19. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors.
Zagar I; Han R; Mitrovic S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):13-6. PubMed ID: 9002742
[TBL] [Abstract][Full Text] [Related]
20. Targeted radionuclide therapy for neuroendocrine tumours.
Lewington VJ
Endocr Relat Cancer; 2003 Dec; 10(4):497-501. PubMed ID: 14713264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
